- Design
- Repeated cross-sectional analysis of national survey data, 1999–2020
- Population
- 12,766 community-dwelling US adults aged ≥65 with a frailty index
- Primary outcome
- Mean number of prescription medications by frailty group
- Effect
- Moderate to severe frailty: 6.0 to 7.8 drugs; mild frailty 3.9 to 5.5; robust 2.0 to 2.9
Using US national survey data from 1999 to 2020, researchers built a frailty index for 12,766 community-dwelling adults aged 65 or over and tracked how many prescription drugs they took.
Medication use rose in every group over two decades. The average went from 2.0 to 2.9 in robust older adults, 3.9 to 5.5 in the mildly frail, and 6.0 to 7.8 in the moderately to severely frail. Cardiovascular drugs made up the largest share but were stable; metabolic drugs rose in all groups, and psychotropic and other central nervous system drugs rose mainly in the frailest.
This is descriptive data from the US, but the pattern is familiar. The frailest patients, who have the least reserve to tolerate adverse effects, carry the heaviest and fastest-growing burden, increasingly from sedating and psychotropic drugs.
For clinicians, frailty should prompt a structured medication review, with particular attention to sedatives, antipsychotics, antidepressants and intensive glucose-lowering in people with limited life expectancy.
- Do a structured medication review whenever a patient is identified as frail
- Look first at sedatives, psychotropics and anticholinergic drugs in frail patients
- Relax glucose and blood pressure targets where frailty and life expectancy justify it
- Count every drug, including over-the-counter and traditional medicines
- Ask what each drug is for and whether it still serves the patient's goals
Why it matters
It shows polypharmacy growing fastest where patients can least tolerate it.
Don't overread it
The data describe US prescribing trends; they do not show which drugs caused harm.
The statistics, in plain English
These are average drug counts from repeated national surveys, not a trial. They show trends, not whether any individual drug was appropriate.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for geriatrics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free